| 1 |
33797709 | Effectiveness of fibroblast growth factor 23 lowering modalities in chronic kidney disease: a systematic review and meta-analysis. | 2022 Feb |
1 |
| 2 |
34061337 | The impact of phosphate lowering agents on clinical and laboratory outcomes in chronic kidney disease patients: a systematic review and meta-analysis of randomized controlled trials. | 2022 Mar |
1 |
| 3 |
34296353 | Elevation of serum fibroblast growth factor 23 level in a pediatric patient with lupus nephritis. | 2022 Feb |
2 |
| 4 |
34459924 | The intersection of mineralocorticoid receptor activation and the FGF23-Klotho cascade: a duopoly that promotes renal and cardiovascular injury. | 2022 Jan 25 |
2 |
| 5 |
34464000 | PTH and FGF23 Exert Interdependent Effects on Renal Phosphate Handling: Evidence From Patients With Hypoparathyroidism and Hyperphosphatemic Familial Tumoral Calcinosis Treated With Synthetic Human PTH 1-34. | 2022 Feb |
8 |
| 6 |
34497173 | Role of adiponectin in the relationship between visceral adiposity and fibroblast growth factor 23 in non-diabetic men with normal kidney function. | 2022 Feb 28 |
3 |
| 7 |
34775773 | Effect of different phosphate binders on fibroblast growth factor 23 levels in patients with chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials. | 2022 Apr |
16 |
| 8 |
34860179 | Perioperative changes of FGF23 in patients undergoing surgery for primary hyperparathyroidism. | 2022 Jan 31 |
3 |
| 9 |
35053218 | Association between Soluble α-Klotho Protein and Metabolic Syndrome in the Adult Population. | 2022 Jan 4 |
1 |
| 10 |
35084563 | The regulation of FGF23 under physiological and pathophysiological conditions. | 2022 Mar |
2 |
| 11 |
35135186 | Tumor - Induced Osteomalacia Associated with a Maxillary Tumor in Children: A Case Report and Review of the Literature. | 2022 Feb 9 |
1 |
| 12 |
35237863 | A review of ferric citrate clinical studies, and the rationale and design of the Ferric Citrate and Chronic Kidney Disease in Children (FIT4KiD) trial. | 2022 Mar 2 |
2 |
| 13 |
35283435 | Contribution of phosphate and FGF23 to CKD progression. | 2022 Jul 1 |
2 |
| 14 |
35288870 | Phosphate-Sensing. | 2022 |
8 |
| 15 |
35288877 | Phosphate Is a Cardiovascular Toxin. | 2022 |
1 |
| 16 |
35338393 | Use of Teriparatide in Hyperphosphatemic Familial Tumor Calcinosis: Evaluating the Interaction Between FGF23 and PTH on the Phosphaturic Effect. | 2022 Mar 25 |
1 |
| 17 |
35399930 | Persistent Lower Limb Deformities Despite Amelioration of Rickets in X-Linked Hypophosphatemia (XLH) - A Prospective Observational Study. | 2022 |
1 |
| 18 |
35482362 | Regulation of 1 and 24 hydroxylation of vitamin D metabolites in the proximal tubule. | 2022 Apr 28 |
1 |
| 19 |
35484227 | Interdisciplinary management of FGF23-related phosphate wasting syndromes: a Consensus Statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia. | 2022 Jun |
1 |
| 20 |
35519919 | Regulation of Calcium Homeostasis in Acute Kidney Injury: A Prospective Observational Study. | 2022 Mar |
1 |
| 21 |
35521770 | 18-year change in serum intact fibroblast growth factor 23 from midlife to late life and risk of mortality: the ARIC Study. | 2022 May 12 |
2 |
| 22 |
35536415 | Disorders of phosphate homeostasis in children, part 1: primer on mineral ion homeostasis and the roles of phosphate in skeletal biology. | 2022 May 10 |
3 |
| 23 |
35536416 | Disorders of phosphate homeostasis in children, part 2: hypophosphatemic and hyperphosphatemic disorders. | 2022 May 10 |
2 |
| 24 |
35589273 | Challenging case of tumour-induced osteomalacia. | 2022 May 19 |
2 |
| 25 |
35629904 | Shedding Light on the Complex Regulation of FGF23. | 2022 Apr 28 |
2 |
| 26 |
32409880 | Congenital Conditions of Hypophosphatemia Expressed in Adults. | 2021 Jan |
3 |
| 27 |
32504139 | New Therapies for Hypophosphatemia-Related to FGF23 Excess. | 2021 Jan |
3 |
| 28 |
32910218 | A unique case of light chain (AL) amyloidosis masquerading as hypophosphatemic osteomalacia. | 2021 Feb |
2 |
| 29 |
32950228 | FGF23 and Cardiovascular Risk. | 2021 Jun |
1 |
| 30 |
32967046 | Interim Analysis of a Phase 2 Open-Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor-Induced Osteomalacia. | 2021 Feb |
2 |
| 31 |
32981786 | Control of phosphorus and prevention of fractures in the kidney patient. | 2021 Jan-Feb |
2 |
| 32 |
33000285 | Fibroblast growth factor 23 (FGF23) level is associated with ultrafiltration rate in patients on hemodialysis. | 2021 Mar |
2 |
| 33 |
33035687 | Fibroblast Growth Factor 23 and Exercise Capacity in Heart Failure with Preserved Ejection Fraction. | 2021 Mar |
2 |
| 34 |
33049075 | C-Terminal, but Not Intact, FGF23 and EPO Are Strongly Correlatively Elevated in Patients With Gain-of-Function Mutations in HIF2A: Clinical Evidence for EPO Regulating FGF23. | 2021 Feb |
2 |
| 35 |
33151412 | Clinicopathologic and molecular features of six cases of phosphaturic mesenchymal tumor. | 2021 Apr |
1 |
| 36 |
33191899 | Hypophosphatemia and FGF23 tumor-induced osteomalacia in two cases of metastatic breast cancer. | 2021 Feb |
1 |
| 37 |
33232874 | Design and development of FGF-23 antagonists: Definition of the pharmacophore and initial structure-activity relationships probed by synthetic analogues. | 2021 Jan 1 |
2 |
| 38 |
33295878 | FGF23-related hypophosphatemic rickets/osteomalacia: diagnosis and new treatment. | 2021 Feb |
4 |
| 39 |
33416083 | Inflammation: a putative link between phosphate metabolism and cardiovascular disease. | 2021 Jan 15 |
2 |
| 40 |
33422302 | [FGF23: from academic nephrology to personalized patient́s care]. | 2021 May-Jun |
3 |
| 41 |
33492457 | Plasma intact fibroblast growth factor 23 level is a useful tool for diagnostic approach of renal hypophosphatemia. | 2021 Apr |
4 |
| 42 |
33564447 | Calciprotein particles and fibroblast growth factor 23 contribute to the pathophysiology of hypercalcemia in a patient with renal sarcoidosis. | 2021 Jan |
1 |
| 43 |
33615106 | Renal Phosphate Handling: Independent Effects of Circulating FGF23, PTH, and Calcium. | 2021 Feb |
3 |
| 44 |
33616712 | Sclerostin Directly Stimulates Osteocyte Synthesis of Fibroblast Growth Factor-23. | 2021 Jul |
2 |
| 45 |
33664928 | A case report of mesenchymal scapular FGF secreting tumor: Importance of follow up in tumor induced osteomalacia. | 2021 Apr |
1 |
| 46 |
33675347 | Antenatal iron supplementation, FGF23, and bone metabolism in Kenyan women and their offspring: secondary analysis of a randomized controlled trial. | 2021 May 8 |
2 |
| 47 |
33706952 | Aging and FGF23-klotho system. | 2021 |
6 |
| 48 |
33715107 | Refractory hypophosphatemia following ferric carboxymaltose administration. | 2021 Nov |
1 |
| 49 |
33716961 | Upstream Regulators of Fibroblast Growth Factor 23. | 2021 |
1 |
| 50 |
33767635 | An Overview of FGF-23 as a Novel Candidate Biomarker of Cardiovascular Risk. | 2021 |
1 |